Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Adjuvant dabrafenib plus trametinib bij stadium III-melanoom: 10 jaar follow-up
aug 2024 | Dermato-oncologie